VTRS Stock Analysis
VT
Uncovered
Viatris Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
13.666
Dividend yield
3.62 %
Shares outstanding
1 196.81 B
Website
https://www.viatris.com/enViatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. The company is headquartered in Canonsburg, Pennsylvania and currently employs 37,000 full-time employees. The Company’s segments include Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries within various markets and economies, as well as its anti-retroviral franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands, complex generics, and biosimilars. The company operates around 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its Viatris Eye Care division is focused on discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases.